```html

Leaflet Heart Valve Disease – A Complete Patient Guide

Overview

Leaflet heart valve disease refers to any disorder that affects the thin, flexible flaps (leaflets) of the heart’s valves. The most commonly involved valves are the aortic and mitral valves, each composed of two or three leaflets that open and close with each heartbeat to direct blood flow.

When leaflets become thickened, calcified, torn, or otherwise abnormal, the valve may stenose (narrow) or become incompetent (leak). Both scenarios force the heart to work harder, eventually leading to symptoms such as breathlessness, fatigue, and swelling.

Who it affects

• Adults age ≥ 60 have the highest prevalence, especially for calcific aortic stenosis.
• Congenital leaflet abnormalities (e.g., bicuspid aortic valve) affect 1–2 % of newborns and often present in younger adults.
• Women are slightly more likely to develop mitral valve prolapse, a leaflet disorder.

Prevalence

• Approximately 10 % of adults over 75 have some form of aortic valve disease.
• Mitral regurgitation (leaflet insufficiency) affects about 2 % of people ≥ 55 years, rising to 10 % in those > 80 years (Mayo Clinic, 2022).

Symptoms

Symptoms vary based on which valve is involved, the severity of the leaflet abnormality, and how fast the disease progresses.

General symptoms common to most leaflet disorders

• Dyspnea (shortness of breath) – especially with exertion or when lying flat (orthopnea).
• Fatigue & reduced exercise tolerance – the heart cannot pump efficiently.
• Palpitations – irregular or rapid heartbeats.
• Chest discomfort – may feel like pressure or tightness, not always classic angina.
• Swelling (edema) – usually in the ankles, feet, or abdomen.
• Syncope or near‑syncope – fainting spells, especially with exertion (a red flag for severe stenosis).

Symptoms by specific valve involvement

Aortic valve leaflet disease (stenosis or regurgitation)

• Chest pain that worsens with activity (angina) – due to reduced coronary perfusion.
• Heart‑sounding murmur heard best at the right upper sternal border.
• Rapid, weak pulse in severe stenosis.

Mitral valve leaflet disease (prolapse, regurgitation, or stenosis)

• Mid‑chest “click” followed by a murmur – classic for mitral valve prolapse.
• Shortness of breath when reclining (paroxysmal nocturnal dyspnea).
• Hoarseness or cough due to left atrial enlargement compressing the airway.

Tricuspid & Pulmonary valve leaflet disease (rare)

• Jugular venous distension and abdominal swelling (right‑sided failure).
• Gentle holosystolic murmur heard at the left lower sternal border.

Causes and Risk Factors

Primary (intrinsic) causes

• Degenerative (calcific) disease – calcium deposits build up on leaflets, most common in the aortic valve after age 65.
• Congenital anomalies – bicuspid aortic valve, valve-sparing connective‑tissue disorders (e.g., Marfan syndrome), or abnormal leaflet size.
• Rheumatic fever – an autoimmune reaction to streptococcal infection that scar tissue the leaflets (still prevalent in low‑income regions).
• Endocarditis – bacterial infection can perforate leaflets or cause vegetations that impair function.
• Myxomatous degeneration – “floppy” leaflets seen in mitral valve prolapse.

Secondary (extrinsic) contributors

• High blood pressure (accelerates aortic stenosis).
• Chronic kidney disease – promotes calcium‑phosphate imbalance and valve calcification.
• Hyperlipidemia – atherosclerotic processes affect valve leaflets.
• Radiation therapy to the chest – can cause fibrosis and calcification.
• Smoking – linked to earlier onset of calcific disease.

Who is at higher risk?

Risk factor	Impact
Age ≥ 65	Strongest predictor of calcific aortic disease
Bicuspid aortic valve	10‑fold increased risk of stenosis before age 50
History of rheumatic fever	Higher likelihood of mitral stenosis
Chronic kidney disease (stage 3‑5)	Accelerated calcium deposition
Male sex (aortic stenosis)	Rates 1.5‑2× higher than women
Female sex (mitral prolapse)	Up to 2× higher prevalence

Diagnosis

Diagnosing leaflet heart valve disease relies on a combination of clinical assessment and imaging.

History & Physical Examination

• Detailed symptom review (timing, triggers, severity).
• Cardiac auscultation – characteristic murmurs, clicks, or gallops guide which valve is involved.
• Assessment for signs of heart failure (elevated jugular venous pressure, peripheral edema).

Imaging & Tests

• Echocardiography (transthoracic – TTE): First‑line, provides valve anatomy, leaflet thickness, motion, gradient measurements, and ejection fraction. 3‑D echo adds detailed leaflet morphology.
• Transesophageal echocardiography (TEE): Higher resolution, especially for mitral valve prolapse or endocarditis.
• Cardiac MRI: Accurate quantification of regurgitant volume and ventricular function; useful when echo windows are poor.
• CT scan: Gold standard for assessing aortic valve calcification score, which predicts progression.
• Electrocardiogram (ECG): Looks for left ventricular hypertrophy, atrial enlargement, or conduction blocks.
• Cardiac catheterization: Reserved for pre‑operative assessment; measures pressures across valve to confirm severity.
• Blood tests: CBC, inflammatory markers (ESR, CRP) for endocarditis; kidney function & lipid panel for risk‑factor management.

Severity Grading

Guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) classify stenosis and regurgitation as mild, moderate, or severe based on valve area, pressure gradients, and regurgitant volume. These categories determine timing of intervention.

Treatment Options

Medication Management (symptom control & risk reduction)

• Diuretics – relieve fluid overload in heart‑failure symptoms.
• Beta‑blockers – lower heart rate, improve diastolic filling in aortic stenosis.
• ACE inhibitors/ARBs – helpful in regurgitant lesions to reduce afterload.
• Anticoagulation – indicated if atrial fibrillation develops (common in mitral disease) or after mechanical valve replacement.
• Statins & antihypertensives – treat underlying atherosclerotic risk (though statins have limited effect on calcific valve progression, they improve overall cardiovascular health).

Procedural Interventions

• Transcatheter Aortic Valve Replacement (TAVR) – minimally invasive placement of a bioprosthetic valve via femoral artery. Preferred for many patients ≥ 75 yr or high surgical risk.
• Surgical Aortic Valve Replacement (SAVR) – open‑heart surgery; choice when annulus anatomy or concomitant coronary disease requires it.
• Mitral Valve Repair – preferred over replacement when feasible; often performed via minimally invasive or robotic approaches.
• Mitral Valve Replacement – indicated for severe leaflet degeneration, calcification, or infective endocarditis.
• Percutaneous Mitral Valve Repair (e.g., MitraClip) – catheter‑based edge‑to‑edge repair for selected high‑risk patients.
• Tricuspid Valve Repair/Replacement – increasingly performed as transcatheter devices emerge.

Lifestyle & Supportive Measures

• Regular, moderate‑intensity aerobic activity (e.g., brisk walking 30 min most days) improves functional capacity.
• Low‑sodium diet (< 2 g/day) to limit fluid retention.
• Weight management – aim for BMI 18.5‑24.9.
• Vaccinations: influenza, COVID‑19, pneumococcal – reduce respiratory infections that can precipitate heart failure.
• Smoking cessation – reduces progression of calcific disease.
• Dental hygiene & prophylactic antibiotics when indicated (e.g., high‑risk prosthetic valve) to prevent endocarditis.

Living with Leaflet Heart Valve Disease

Monitoring & Follow‑up

• Echocardiogram schedule:
  • Mild disease – every 2‑3 years.
  • Moderate disease – annually.
  • Severe disease – every 6‑12 months or sooner if symptoms change.
• Keep a symptom diary – note exertional breathlessness, swelling, or palpitations.
• Know your target heart‑rate range (often 50‑60 % of predicted max for severe stenosis). Use a pulse watch or smartphone app.

Daily‑life tips

• Energy pacing: Break activities into short bouts with rest periods.
• Hydration balance: Adequate fluids unless advised otherwise for severe regurgitation with heart failure.
• Travel considerations: Carry medication, a copy of recent echo, and emergency contact info; consider altitude effects on oxygenation.
• Work & driving: Most patients with mild‑moderate disease can drive safely; severe disease with syncope requires physician clearance.
• Support networks: Join heart‑valve patient groups (e.g., American Heart Association’s “Heart Valve Hub”).

Prevention

Primary prevention – reducing risk of leaflet disease

• Control blood pressure and cholesterol (American Heart Association guidelines).
• Maintain renal health – adequate hydration, avoid nephrotoxic drugs.
• Prompt treatment of streptococcal throat infections to prevent rheumatic fever.
• Adopt a heart‑healthy diet rich in fruits, vegetables, whole grains, omega‑3 fatty acids, and limited red meat.
• Regular physical activity – at least 150 min/week of moderate‑intensity aerobic exercise.
• Avoid excessive calcium supplementation in patients with known valve calcification unless prescribed.

Secondary prevention – slowing progression after diagnosis

• Strict adherence to medication regimens.
• Periodic imaging to catch accelerated stenosis or worsening regurgitation early.
• Manage comorbidities (diabetes, sleep apnea, COPD).
• Vaccinations and infection control to prevent endocarditis episodes.

Complications

If left untreated or if disease progresses despite optimal therapy, several serious complications can arise:

• Heart failure – the most common consequence; can be left‑sided (pulmonary congestion) or right‑sided (systemic edema).
• Atrial fibrillation – especially with mitral valve disease; increases stroke risk.
• Stroke or systemic embolism – from thrombus formation on diseased leaflets or in the left atrium.
• Infective endocarditis – damaged leaflets are a nidus for bacterial colonization.
• Sudden cardiac death – particularly in severe aortic stenosis with left ventricular outflow obstruction.
• Pulmonary hypertension – chronic left‑sided pressure overload can transmit backward to the lungs.

When to Seek Emergency Care

---

Sources: Mayo Clinic, American Heart Association, CDC, National Institutes of Health (NIH), World Health Organization (WHO), ACC/AHA 2024 Guideline for the Management of Valvular Heart Disease, European Society of Cardiology 2023 Valve Recommendations.

```